PetLife Pharmaceuticals Applies for VitalZul Patent

PetLife Pharmaceuticals (OTCQB:PTLF) revealed it filed for patent protection in India and the US for VitalZul, their pet cancer treatment.
As quoted in the press release:

The Company, through an officer of the Company, has filed for a patent in India titled, A Composition for Targeting Cancer in Canines and Humans. The patent protection is for both process and composition thus protecting not only the physical elements of our formulation but also the process by which they are combined. The patent formulation is intended for both animal and human use, pending further testing.
The filing in the United States was titled the same as the India patent with the same attributes as filed in India.
The elements of the formulation of VitalZul™ have been shown to have extremely minimal toxicity. The components of the formulation are natural, not synthetic.
Dr. Ralph Salvagno, CEO of PetLife, stated, “Our team of scientists and researchers in India and in the U.S. have worked diligently to bring VitalZul™ to the next stage of our growth plan. With the patents filed, we will continue the course towards our FDA application. The goal is to bring VitalZul™ to market by the end of 2018.”

Click here to read the full press release.

Source: www.accesswire.com